Pure Global
NCT06401642

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

A Study to Assess Effectiveness and Tolerability of Zavegepant as an Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications.
Mayo Clinic·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Migraine
Drug/Device/Intervention
Zavegepant
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mayo Clinic
Location
Scottsdale, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
May 01, 2024
End date
Mar 01, 2027
Enrollment
200 participants
Primary outcome

Headache relief in 2 hours,Headache relief in 4 hours,Functional disability level in 2 hours,Functional disability level in 4 hours

Summary

Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in
 the US. The purpose of this study is to investigate the effectiveness and tolerability of
 zavegepant for the acute treatment of migraine attacks amongst participants who are using
 calcitonin gene-related peptide (CGRP) migraine preventive treatments.

ICD-10 classifications
MigraineOther migraineMigraine, unspecifiedComplicated migraineHeadache
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06401642
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06401642 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Migraine. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.